Fierce Pharma

SEPTEMBER 14, 2023

Amid the Federal Trade Commission's (FTC's) campaign to bolster scrutiny around large biopharma M&A deals, the agency is now taking a closer look at patent gamesmanship. |

Biopharma 266

Biopharma Pharmaceutical 266

Fierce Pharma

APRIL 18, 2023

Embracing Personalization in Biopharma Patient Support Programs mteefey Tue, 04/18/2023 - 14:48

Biopharma 246

Biopharma Patients 246

Zymewire

JULY 24, 2024

As the second quarter of 2024 comes to a close, the biopharma landscape continues to evolve with dynamic shifts in funding, clinical trials, and innovative developments. Zymewire is back to provide you with a comprehensive digest of what's happened in Q2, to help inform smarter business decisions going forward.

Biopharma 52

Biopharma 52

Fierce Pharma

JUNE 14, 2023

billion buyout of Horizon Therapeutics has raised concerns that the United States’ antitrust watchdog is tightening the screws on major M&A moves in the biopharma industry. An FTC lawsuit aimed at blocking Amgen’s $27.8 billion buyout o | An FTC lawsuit aimed at blocking Amgen’s $27.8

Biopharma 293

Biopharma 293

Fierce Pharma

MAY 22, 2023

Pfizer, Moderna among many biopharma giants to post Q1 sales declines, as Novo Nordisk led growth charge kdunleavy Mon, 05/22/2023 - 13:04

Biopharma 300

Biopharma Sales 300

Fierce Pharma

MARCH 21, 2023

Biopharma industry lobbies for tax breaks related to US-based manufacturing kdunleavy Tue, 03/21/2023 - 11:14

Biopharma 261

Biopharma Manufacturing 261

PharmaTech

JULY 23, 2024

The addition of BIOVECTRA’s biologics capabilities to accelerate drug development and manufacturing will allow Agilent to expand its end-to-end offerings for biopharma services.

Biopharma 59

Biopharma Manufacturing 59

Fierce Pharma

MAY 16, 2023

FTC seeks to block Amgen's $28B Horizon buy in 'broadly negative' move for biopharma M&A: report aliu Tue, 05/16/2023 - 09:41

Biopharma 293

Biopharma 293

Fierce Pharma

DECEMBER 21, 2022

Tamiflu generics in short supply in latest chapter of biopharma's shortage saga. fkansteiner. Wed, 12/21/2022 - 08:40.

Biopharma 252

Biopharma 252

European Pharmaceutical Review

DECEMBER 30, 2023

The past 12 months has seen significant growth in global mergers and acquisitions (M&A) within the biopharma sector. This activity is expected to continue in 2024, with increasing need for biopharma to access innovation through collaboration and dealmaking to offset looming patent challenges. “In

Biopharma 105

Biopharma Marketing Prospecting Pharmaceutical 105

Fierce Pharma

JUNE 26, 2023

But there was no evidence of the slide in biopharma where pay increases were plentiful. There was a decline in CEO compensation overall in 2022.

Biopharma 176

Biopharma 176

Fierce Pharma

MAY 25, 2023

The Top Line': The 20 most influential people in biopharma, plus this week's headlines tcarey Thu, 05/25/2023 - 14:21

Biopharma 241

Biopharma 241

Fierce Pharma

APRIL 19, 2023

Alnylam, Intra-Cellular among analyst's top picks for M&A as biopharma dealmaking heats up aliu Wed, 04/19/2023 - 14:39

Biopharma 243

Biopharma 243

Fierce Pharma

MAY 9, 2023

Let's make a deal: Conditions are right for biopharma M&A to break out, analysts say kdunleavy Tue, 05/09/2023 - 10:18

Biopharma 246

Biopharma 246

Fierce Pharma

DECEMBER 20, 2022

2023 forecast: An 'inflection point' for biopharma, fueled by a flood of AI and machine learning products. Tue, 12/20/2022 - 13:39.

Biopharma 261

Biopharma 261

Fierce Pharma

JULY 18, 2024

As biopharma companies and the U.S. | As biopharma companies and the U.S. government near the deadline of their drug price talks under the Inflation Reduction Act, Novartis CEO said the cost cuts “might be manageable” in the short term for the firm’s first few products to be included.

Management 267

Management Biopharma Government 267

Pharmaceutical Technology

MARCH 8, 2024

Johnson & Johnson (J&J) has concluded the acquisition of Ambrx Biopharma in a transaction valued at approximately $2bn.

Biopharma 111

Biopharma 111

Fierce Pharma

JULY 2, 2024

Even as the BIOSECURE Act charts an uncertain path through the legislative process, the draft bill has already seriously harmed the U.S. Even as the BIOSECURE Act works its way through the legislative process, the draft bill has already caused a slide in U.S. life sciences companies' confidence in Chinese partners, a new survey has found.

Biopharma 274

Biopharma 274

MedCity News

JUNE 18, 2024

The post Cancer Biotech Day One Biopharma Expands to ADCs, Paying $55M to Nab a Phase 1-Ready Drug appeared first on MedCity News. Day One Biopharmaceuticals is adding an antibody drug conjugate to its pipeline, licensing rights to a molecule from MabCare Therapeutics.

Biopharma 102

Biopharma Pharma 102

Fierce Pharma

MAY 9, 2023

We want your stories: Biopharma's collective memory of COVID—in photographs aliu Tue, 05/09/2023 - 14:56

Biopharma 157

Biopharma 157

MedCity News

OCTOBER 3, 2023

Acquiring Point Biopharma gives Eli Lilly a pipeline of radiopharmaceuticals, including one for prostate cancer that could rival Novartis’s Pluvicto. The deal comes ahead of an expected Phase 3 data readout for that Point therapeutic candidate.

Biopharma 117

Biopharma Pharma 117

European Pharmaceutical Review

JUNE 7, 2023

The global biopharma industry’s resilience has decreased since 2021, a report by Cytiva has found. Using feedback from 1250 pharma and biopharma executives in 22 countries, the research sought to find out how has the biopharma industry has evolved over the past two years and what areas the industry should seek to improve.

Biopharma 97

Biopharma Government Manufacturing Pharma 97

MedCity News

FEBRUARY 16, 2024

It’s time for the biopharma industry to embrace end-to-end digitalization. Moving from spreadsheets to automated data collection and processing is far from easy, but it could revolutionize drug development.

Biopharma 106

Biopharma 106

Fierce Pharma

MAY 18, 2023

The Top Line': 2023's biopharma layoffs, plus this week's headlines tcarey Thu, 05/18/2023 - 16:13

Biopharma 144

Biopharma 144

Fierce Pharma

MAY 10, 2024

Right after an industry survey suggested that switching away from Chinese CDMOs could take biopharma companies up to eight years, lawmakers have adjusted the BIOSECURE Act. The new draft lays out a 2032 deadline for the separation mandate.

Biopharma 345

Biopharma 345

Fierce Pharma

MAY 1, 2024

Just about two months into his CEO job at Emergent BioSolutions, Joseph Papa has laid out his turnaround plan for the CDMO-turned-biopharma company. Merely about two months into his CEO job at Emergent BioSolutions, Joseph Papa has laid out his turnaround plan for the CDMO-turned-biopharma company.

Biopharma 339

Biopharma 339

Fierce Pharma

JULY 12, 2024

With a new production line up and running at its latest facility in the greater Boston area, family-owned German CDMO Rentschler Biopharma is eager to court new clients. The company already has one “major project” underway utilizing the new production tech, plus several additional projects in the pipeline.

Manufacturing 241

Manufacturing Biopharma 241

Fierce Pharma

JUNE 4, 2024

security crackdown on biopharma firms suspected to be linked to the Chinese Communist Party (CCP) has continued to gain steam. | security crackdown on biopharma firms suspected to be linked to the Chinese Communist Party has continued to gain steam. For several months, a U.S. For several months, a U.S.

Biopharma 301

Biopharma 301

European Pharmaceutical Review

APRIL 17, 2023

A report on automation in the biopharma industr y has shown that the market is projected to grow at a compound annual growth rate (CAGR) of 5.7 Factors impacting the automation in the biopharma industry market The report found that 75 percent of pharmaceutical organisations want to use automated solutions more frequently.

Biopharma 98

Biopharma Manufacturing Pharmaceutical products Marketing 98

European Pharmaceutical Review

JULY 7, 2023

New recommendations to boost the competitiveness in UK biopharma and Medtech sectors have been published by Imperial College London. Technological solutions and policy recommendations for government have been identified as a way to help make sectors such as biopharma and Medtech more innovative and increase their value added.

Competition 104

Competition Biopharma Government Manufacturing 104

PharmExec

AUGUST 21, 2023

In this exclusive Q&A with Pharmaceutical Executive, Janice Chang, CEO of TransCelerate BioPharma, provides an inside look into her career journey, her work at the company, how the industry has changed in the last 10 years, as well as her thoughts on where the industry should put its efforts in clinical trials.

Biopharma 97

Biopharma Pharmaceutical 97

PharmaTech

JANUARY 24, 2024

Under a new alliance, KBI Biopharma and Argonaut Manufacturing Services will combine their strengths to offer end-to-end biopharma development and CGMP manufacturing solutions.

Biopharma 98

Biopharma Manufacturing 98

European Pharmaceutical Review

SEPTEMBER 4, 2023

The biopharma company will be required to seek prior approval before acquiring related products. Divest to invest: the new normal in biopharma? The post FTC order could ease biopharma competition appeared first on European Pharmaceutical Review. The FTC has settled on a proposed consent order with Amgen Inc.

Competition 98

Competition Biopharma Pharmaceutical Government 98

MedCity News

AUGUST 21, 2023

Healthcare M&A deals are expected to pick up over the next few months, and one expert is predicting that the biopharma sector in particular will see especially robust activity.

Biopharma 97

Biopharma Marketing Healthcare Healthcare 97

PharmaTech

JANUARY 10, 2024

Franco Negron, CEO, Simtra BioPharma Solutions, discusses the company's expertise in supporting the development and manufacture of sterile injectables, its integrated approach to project management, and his expectations regarding the company's future in the industry.

Biopharma 59

Biopharma Manufacturing Management 59

Fierce Pharma

JANUARY 23, 2023

Call for nominations: The most influential people in biopharma in 2023 esagonowsky Mon, 01/23/2023 - 14:32

Biopharma 130

Biopharma 130

PharmaVoice

JUNE 13, 2023

Collaboration is important along the entire spectrum and lifecycle of biopharma, and finding an effective partner is harder than it sounds.

Biopharma 105

Biopharma 105